The Effectiveness of Phytotherapy in SARS-COV2(COVID-19) (Quercetix)

Hôpital Universitaire Sahloul

Status and phase: Completed; Phase 1

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2); a Randomized Double-blind Study; PHYTOTHERAPIE

Treatments: Drug: Quercetin

Study type: Interventional

Funder types: Other

Identifiers

NCT04851821

Quercetix

Details and patient eligibility

About

Quercetin is one of the flavonoids. Quercetin as well as rutin are recognized to be among the most active of the flavonoids. It is to quercetin that several medicinal plants, including ginkgo and St. John's Wort, owe part of their therapeutic effects. Often combined with vitamin C in supplements, it improves absorption by the body and delays its elimination.

Quercetin is extracted from a variety of plant sources, including the onion peel and seeds and pods of Dimorphandra mollis, a tree in the legume family native to South America.

At present, there is no scientific data to demonstrate the effectiveness of herbal medicine, regardless of the plant, to prevent or treat COVID-19. On the other hand, some plant-based food supplements have anti-inflammatory or immunomodulatory properties that may disrupt inflammatory defense mechanisms useful in fighting infections, and in particular against COVID-19.

Full description

Type of study: a randomized, double-blind study using the Quercetine in the treatment of patients with SARS COV2 (covid-19) Quercetin is extracted from a variety of plant sources, including the onion peel and the seeds and pods of Dimorphandra mollis, a legume tree native to South America.

Although we are far from knowing everything about quercetin, its antioxidant, anti-inflammatory, and antihistamine (antiallergic) properties have been observed in numerous in vitro and animal studies.

History on quercetin In 1937, Albert Szent-Gyorgyi received a Nobel Prize for discovering vitamin C and flavonoids, as well as for exploring their biochemical properties. Originally, he gave the flavonoids the name "vitamin P" because of their effectiveness in reducing the permeability of blood vessels. This name was abandoned when it was realized that these substances were not really vitamins.

Enrollment: 80 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• all patients attending the emergency department for influenza-like illness.
• Being over 18 years old

Exclusion criteria

• Any patient requiring admission
• Non-consenting patients

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

80 participants in 2 patient groups, including a placebo group

Quercetix group

Experimental group

Description:

Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.

Treatment:

Drug: Quercetin

Placebo Group

Placebo Comparator group

Description:

Each patient included, after signing the consent, will have a treatment for ten days: one tablet twice a day 30 minutes before the meal.

Treatment:

Drug: Quercetin